<SUBMISSION>
<ACCESSION-NUMBER>0001144204-06-021855
<TYPE>10QSB
<PUBLIC-DOCUMENT-COUNT>5
<PERIOD>20060331
<FILING-DATE>20060522
<DATE-OF-FILING-DATE-CHANGE>20060522
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED BIOTHERAPY INC
<CIK>0000791833
<ASSIGNED-SIC>8731
<IRS-NUMBER>510402415
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>10QSB
<ACT>34
<FILE-NUMBER>000-26323
<FILM-NUMBER>06856956
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
<PHONE>818-8833956
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED BIOTHERAPY CONCEPTS INC
<DATE-CHANGED>19990524
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>10QSB
<SEQUENCE>1
<FILENAME>v043962_10-qsb.txt
<TEXT>
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                   FORM 10-QSB

                                   (Mark One)

|X|   Quarterly report pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934 for the period ended March 31, 2006
                                       OR
|_|   Transition report pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934 for the transition period from ____________ to
      ______________

                         Commission file number 0-26323

                            ADVANCED BIOTHERAPY, INC.
             (Exact name of registrant as specified in its charter)

          Delaware                                               51-0402415
  (State of jurisdiction of                                    (IRS Employer
incorporation or organization)                               Identification No.)

                          6355 Topanga Canyon Boulevard
                                    Suite 510
                        Woodland Hills, California 91367
          (Address of principal executive offices, including zip code)

                                 (818) 883-6716
              (Registrant's telephone number, including area code)

Indicate by mark whether the Registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. |X| YES |_| NO

As of May 6, 2006, the Registrant had 54,348,346 shares of common stock, $0.001
par value, outstanding.

      ---------------------------------------------------------------------

<PAGE>

                                TABLE OF CONTENTS

ITEM                                                                        PAGE

                                     PART I.

1.  Financial Statements
    a.   Balance Sheets - March 31, 2006 (unaudited) and December 31,
         2005..................................................................1
    c.   Statements of Operations -- Three Months Ended March 31, 2006
         (unaudited), March 31, 2005 (unaudited), and from Inception
         through March 31, 2006 (unaudited)....................................2

    d.   Statement of Cash Flows - Three Months Ended March 31, 2006
         (unaudited), March 31, 2005 (unaudited) and from Inception
         through March 31, 2006 (unaudited)....................................3

    e.   Notes to Financial Statements.........................................4

2.  Management's Discussion and Analysis of Financial Condition
    and Results of Operations.................................................10

3.  Controls and Procedures...................................................13

                                    PART II.

6.  Exhibits and Reports on Form 8-K..........................................14

<PAGE>

PART I

ITEM 1. FINANCIAL STATEMENTS

<PAGE>

ADVANCED BIOTHERAPY, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
BALANCE SHEETS
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                                        March 31,
                                                                           2006        December 31,
                                                                       (Unaudited)         2005
                                                                       ------------    ------------
<S>                                                                    <C>             <C>
ASSETS

  CURRENT ASSETS
    Cash                                                               $      9,265    $     22,068
    Notes receivable - related party                                         46,619          46,619
    Interest receivable - related party                                      18,848          18,090
    Deposits and prepaid expenses                                                --              --
                                                                       ------------    ------------
         Total Current Assets                                                74,732          86,777
                                                                       ------------    ------------

  PROPERTY, PLANT AND EQUIPMENT, net                                        289,445         294,428
                                                                       ------------    ------------

  OTHER ASSETS
    Deferred loan origination fees, net of accumulated amortization           2,524           7,283
    Patents and patents pending, net of accumulated amortization            881,147         883,002
                                                                       ------------    ------------
         Total Other Assets                                                 883,671         890,285
                                                                       ------------    ------------

TOTAL ASSETS                                                           $  1,247,848    $  1,271,490
                                                                       ============    ============

LIABILITIES AND STOCKHOLDERS' DEFICIT

  CURRENT LIABILITIES
    Accounts payable and accrued expenses                              $    229,122    $    246,776
    Accounts payable and accrued expenses - related party                   242,501         182,200
    Loan payable - related party                                                 --              --
    Accrued interest on term and convertible debt                           165,326              --
    Current portion of term and convertible notes payable                 4,640,486       4,490,485
    Other Current Liabilities                                                    --              --
                                                                       ------------    ------------
         Total Current Liabilities                                        5,277,435       4,919,461
                                                                       ------------    ------------

  LONG-TERM DEBT
    Convertible notes payable, net of current portion                     1,286,133       1,286,134
    Note payable to related parties                                         127,631         127,631
                                                                       ------------    ------------
         Total Long-Term Debt                                             1,413,764       1,413,765
                                                                       ------------    ------------

  TOTAL LIABILITIES                                                       6,691,199       6,333,226
                                                                       ------------    ------------

  COMMITMENTS AND CONTINGENCIES                                                  --              --
                                                                       ------------    ------------

  STOCKHOLDERS' DEFICIT
    Preferred stock, par value $0.001; 20,000,000 shares authorized,
      no shares issued and outstanding                                           --              --
    Common stock, par value $0.001; 200,000,000 shares authorized,
      54,348,346 shares issued and outstanding                               54,347          54,347
    Additional paid-in capital                                            6,989,112       6,948,814
    Stock options and warrants                                            1,348,051       1,235,551
    Deficit accumulated during development stage                        (13,834,861)    (13,300,448)
                                                                       ------------    ------------
         Total Stockholders' Deficit                                     (5,443,351)     (5,061,736)
                                                                       ------------    ------------

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT                            $  1,247,848    $  1,271,490
                                                                       ============    ============
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                       1
<PAGE>

ADVANCED BIOTHERAPY, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
STATEMENTS OF OPERATIONS
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                                           From Inception
                                                                         (December 2, 1985)
                                               Quarter Ended March 31,         through
                                            ----------------------------      March 31,
                                                2006           2005             2006
                                            (Unaudited)     (Unaudited)      (Unaudited)
                                            ------------    ------------    ------------
<S>                                         <C>             <C>             <C>
REVENUES                                    $         --    $         --    $     89,947
                                            ------------    ------------    ------------

OPERATING EXPENSES
  Research and development                         2,597          93,685       3,918,131
  Promotional fees                                    --              --          62,570
  Professional fees                               42,418          70,663       3,003,492
  Business development                            39,500              --         121,000
  Vesting of stock options and warrants          151,700         172,200       1,383,309
  Warrants - scientific advisory board                --              --           1,900
  Directors' fees                                     --              --         299,053
  Depreciation and amortization                   26,105          24,707         906,511
  Administrative salaries and benefits            92,196          69,177       1,470,194
  Insurance                                           --          18,257         324,452
  Shareholder relations and transfer fees          3,000           8,690         314,398
  Rent                                             5,100           5,100         356,478
  Travel and entertainment                            35          13,568         330,834
  Telephone and communications                       843           1,791          63,260
  Office                                           1,371           1,773          83,239
  General and administrative                       4,062           5,984         755,818
                                            ------------    ------------    ------------
      Total Operating Expenses                   368,927         485,595      13,394,639
                                            ------------    ------------    ------------

LOSS FROM OPERATIONS                            (368,927)       (485,595)    (13,304,692)

OTHER INCOME (EXPENSES)
  Miscellaneous income                                --             250          27,682
  Interest and dividend income                       938           1,850         172,377
  Internal gain on sale of securities                 --              --         157,520
  Forgiveness of debt                                 --              --       2,192,837
  Forgiveness of payables                             --              --          45,396
  Loss on disposal of office equipment                --              --          (2,224)
  Loss on abandonment of patents                      --                         (43,675)
  Interest expense                              (166,424)       (139,571)     (3,080,082)
                                            ------------    ------------    ------------
      Total Other Income (Expenses)             (165,486)       (137,471)       (530,169)
                                            ------------    ------------    ------------

LOSS BEFORE INCOME TAXES                        (534,413)       (623,066)    (13,834,861)

INCOME TAXES                                          --              --              --
                                            ------------    ------------    ------------

NET LOSS                                    $   (534,413)   $   (623,066)   $(13,834,861)
                                            ============    ============    ============

  BASIC AND DILUTED NET LOSS
  PER COMMON SHARE                          $      (0.01)   $      (0.01)
                                            ============    ============

  WEIGHTED AVERAGE NUMBER OF
  BASIC AND DILUTED COMMON STOCK
  SHARES OUTSTANDING                          54,348,346      54,032,557
                                            ============    ============
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                       2
<PAGE>

ADVANCED BIOTHERAPY, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
STATEMENTS OF CASH FLOWS
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                                                       From Inception
                                                                                     (December 2, 1985)
                                                           Quarter Ended March 31,         through
                                                            2006             2005      March 31, 2006
                                                        (Unaudited)      (Unaudited)     (Unaudited)
                                                        ------------    ------------    ------------
<S>                                                     <C>             <C>             <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
  Net (loss)                                            $   (534,413)   $   (623,066)   $(13,834,861)
  Adjustments to reconcile net loss to cash
  used in operating activities:
    Depreciation and amortization                             26,105          24,707         848,623
    Loss on disposal of equipment                                                 --           2,224
    Loss on impairment of patents                                                 --          43,675
    Investment income                                                             --        (157,520)
    Expenses paid through issuance of common stock                                --         291,339
    Expenses paid through issuance                                                --
      of common stock warrants and options                   151,700         214,600       1,551,162
    Accrued interest paid by convertible debt                                     --       2,523,549
    Expenses paid through contribution
      of additional paid-in capital                            1,098           1,098          65,844
    Organization costs                                                            --          (9,220)
    Decrease (increase) in assets:                                                                --
        Marketable securities                                                     --              --
        Deposits and prepaid expenses                                         (5,887)             --
        Interest receivable                                     (758)           (758)        (59,416)
        Deferred loan origination cost                                            --        (157,295)
    Increase (decrease) in liabilities:                                                           --
        Accounts payable and accrued expenses                (17,654)         65,873         306,663
        Accounts payable and accrued expenses -
          related parties                                     60,301         (31,393)        301,469
        Accrued Interest                                     165,326         139,571              --
                                                        ------------    ------------    ------------

           Net cash used in operating activities            (148,295)       (215,255)     (8,283,764)
                                                        ------------    ------------    ------------

CASH FLOWS FROM INVESTING ACTIVITIES:
  Purchase of fixed assets                                                      (858)       (385,339)
  Acquisition of patents                                     (14,508)        (23,985)             --
                                                        ------------    ------------    ------------

            Net cash used in investing activities            (14,508)        (24,843)       (385,339)
                                                        ------------    ------------    ------------

CASH FLOWS FROM FINANCING ACTIVITIES:
  Proceeds from issuance of common stock                          --              --       2,457,254
  Internal gain on sale of securities                             --              --         157,520
  Proceeds from convertible notes                                 --              --       6,754,000
  Proceeds from notes payable                                150,000              --         538,508
  Payments on notes payable                                       --              --              --
                                                        ------------    ------------    ------------

            Net cash provided by financing activities        150,000              --       9,907,282
                                                        ------------    ------------    ------------

  Net increase (decrease) in cash                            (12,803)       (240,098)          9,265

  Cash beginning                                              22,068         367,337              --
                                                        ------------    ------------    ------------

  Cash, ending                                          $      9,265    $    127,239    $      9,265
                                                        ============    ============    ============

SUPPLEMENTAL CASH FLOW DISCLOSURES:

  Interest expense paid                                 $         --    $        128    $    341,166
                                                        ============    ============    ============
  Income taxes paid                                     $         --    $         --    $         --
                                                        ============    ============    ============

NON-CASH FINANCING AND INVESTING ACTIVITIES:

  Common stock issued in exchange for
     professional fees and expenses                     $         --    $         --    $    400,868
  Contributed expenses                                  $      1,098    $      1,098    $     65,844
  Common stock issued for a loan payable                $         --    $         --    $    213,381
  Common stock issued for notes receivable              $         --    $         --    $    246,619
  Common stock returned in payment of
     notes and interest receivable                      $         --    $         --    $    240,568
  Warrants and options issued for services
     and accrued expenses                               $    151,700    $    214,600    $  1,551,162
  Common stock issued on cashless exercise of
     warrants                                           $         --    $         --    $     15,011
  Accrued interest paid by convertible debt             $         --    $         --    $  2,523,549
  Common stock issued for convertible debt              $         --    $         --    $    707,156
  Forgiveness of debt                                   $         --    $         --    $    145,400
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                       3
<PAGE>

ADVANCED BIOTHERAPY, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
CONDENSED NOTES TO FINANCIAL STATEMENTS
March 31, 2006
--------------------------------------------------------------------------------

NOTE 1 - BUSINESS ORGANIZATION AND BASIS OF PRESENTATION

Advanced Biotherapy, Inc. was originally incorporated December 2, 1985 under the
laws of the State of Nevada as Advanced Biotherapy Concepts, Inc. On July 14,
2000, the Company incorporated a wholly owned subsidiary, Advanced Biotherapy,
Inc. in the State of Delaware. On September 1, 2000, the Company merged with its
wholly owned subsidiary, effectively changing its name to Advanced Biotherapy,
Inc. (hereinafter "the Company" or "ABI") and its domicile to Delaware.

The Company is involved in the research and development for the treatment of
autoimmune diseases in humans, most notably, multiple sclerosis, rheumatoid
arthritis, and certain autoimmune skin diseases and AIDS. The Company conducts
its research in Maryland. The Company's fiscal year-end is December 31. The
Company is a development stage enterprise.

The Company has been in the development stage since its formation in 1985 and
has not realized any significant revenues from its planned operations. It is
primarily engaged in the research and development of the treatment of autoimmune
diseases in humans, most notably, multiple sclerosis and rheumatoid arthritis.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern.

For the three months ended March 31, 2006, the Company incurred a net loss of
$534,413 and had an accumulated deficit during the development stage of
$13,834,861. The Company has limited funds for research and development costs
and operations and it does not have a source of revenues to continue its
operations, research and development costs or to service its debt at maturity.
For the twelve-month period subsequent to March 31, 2006, the Company
anticipates that its minimum cash requirements to continue as a going concern
will be approximately $1,800,000 for operations and approximately $4,600,000 to
repay the current portion of convertible debt. The future of the Company is
dependent upon securing additional debt or equity funding and future profitable
operations from the commercial success of its medical research and development
of products to combat diseases of the human immune system. Management's goal is
to forge a collaborative relationship with either a pharmaceutical or
biotechnology company. If successful, future cash requirements may be met
through licensing fees and royalties. The financial statements do not include
any adjustments relating to the recoverability and classification of recorded
assets, or the amounts and classification of liabilities that might be necessary
in the event the Company cannot continue in existence.

The foregoing unaudited interim financial statements have been prepared in
accordance with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-QSB and Regulation S-B as
promulgated by the Securities and Exchange Commission ("SEC"). Accordingly,
these financial statements do not include all of the disclosures required by
generally accepted accounting principles in the United States of America for
complete financial statements. These unaudited financial statements should be
read in conjunction with the audited financial statements for the year ended
December 31, 2005. In the opinion of management, the unaudited interim financial
statements furnished herein include all adjustments, all of which are of a
normal recurring nature, necessary for a fair statement of the results for the
interim period presented. Operating results for the three month period ended
March 31, 2006 are not necessarily indicative of the results that may be
expected for the year ending December 31, 2006.

                                       4
<PAGE>

ADVANCED BIOTHERAPY, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
CONDENSED NOTES TO FINANCIAL STATEMENTS
March 31, 2006
--------------------------------------------------------------------------------

NOTE 2 - LIMITED SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant accounting policies of the Company is presented to
assist in understanding the Company's financial statements. The financial
statements and notes are representations of the Company's management, which is
responsible for their integrity and objectivity. These accounting policies
conform to accounting principles generally accepted in the United States of
America, and have been consistently applied in the preparation of the financial
statements.

Accounting Method
The Company's financial statements are prepared using the accrual method of
accounting.

Use of Estimates
The process of preparing financial statements in conformity with accounting
principles generally accepted in the United States of America requires the use
of estimates and assumptions regarding certain types of assets, liabilities,
revenues, and expenses. Such estimates primarily relate to unsettled
transactions and events as of the date of the financial statements. Accordingly,
upon settlement, actual results may differ from estimated amounts.

Accounting for Stock Options and Warrants Granted to Employees and Nonemployees
Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based
Compensation", defines a fair value-based method of accounting for stock options
and other equity instruments. The Company has adopted this method, which
measures compensation costs based on the estimated fair value of the award and
recognizes that cost over the service period.

Development Stage Activities
The Company has been in the development stage since its formation in 1985 and
has not realized any significant revenues from its planned operations. It is
primarily engaged in the research and development of the treatment of autoimmune
diseases in humans, most notably, multiple sclerosis and rheumatoid arthritis.

Research and Development
Costs of research and development are expensed as incurred.

                                       5
<PAGE>

ADVANCED BIOTHERAPY, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
CONDENSED NOTES TO FINANCIAL STATEMENTS
March 31, 2006
--------------------------------------------------------------------------------

NOTE 3 - PROPERTY AND EQUIPMENT

Property and equipment are stated at cost. Depreciation is provided using the
straight-line method over the estimated useful lives of the assets of three to
thirty-nine years.

The following is a summary of property, equipment and accumulated depreciation
at March 31, 2006 and December 31, 2005:

                                                     March 31,     December 31,
                                                       2006            2005
                                                   ------------    ------------
                                                       Cost            Cost
                                                   ------------    ------------
Lab equipment                                      $     31,891    $     31,891
Office equipment                                         13,777          13,777
Furniture and fixtures                                   22,539          22,539
Clean room                                              271,786         271,786
                                                   ------------    ------------
    Total assets                                        339,993         339,993
Less accumulated depreciation                           (50,548)        (45,565)
                                                   ------------    ------------
    Net fixed assets                               $    289,445    $    294,428
                                                   ============    ============

Depreciation and amortization expense for the three months ended March 31, 2006
and 2005 were $4,983 and $5,344, respectively.

NOTE 4 - CAPITAL STOCK

Preferred Stock
The Company is authorized to issue 20,000,000 shares of non-assessable $0.001
par value preferred stock. As of March 31, 2006, the Company has not issued any
preferred stock.

Common Stock
The Company is authorized to issue 200,000,000 shares of non-assessable $0.001
par value common stock. Each share of stock is entitled to one vote at the
annual shareholders' meeting. No common stock shares were issued during the
three months ending March 31, 2006.

NOTE 5 - COMMON STOCK OPTIONS AND WARRANTS

Omnibus Equity Incentive Plan
In 2000, the board of directors approved an Omnibus Equity Incentive Plan, which
was later approved by the stockholders in December 2001. The purpose of the plan
is to promote the long-term success of the Company and the creation of
stockholder value by encouraging employees, outside directors and consultants to
focus on the achievement of critical long-range objectives. The plan endeavors
to attract and maintain such individuals with exceptional qualifications and to
link them directly to stockholder interests through increased stock ownership.
The plan seeks to achieve this purpose by providing for awards in the form of
restricted shares, stock units, options (which may constitute incentive stock
options or non-statutory stock options) and stock appreciation rights ("SAR's").
The aggregate number of options, SARs, stock units and restricted shares awarded
under the plan was initially 4,000,000 common shares plus an annual increase of
the lesser of two and one-half percent of the total number of common shares then
outstanding or 250,000 common shares. No options were issued under this plan
during the three months ending March 31, 2006. However, 1,200,000 options vested
during the first quarter of 2006, and the resulting expense of $147,600 was
recorded in the accompanying statement of operations.

                                       6
<PAGE>

ADVANCED BIOTHERAPY, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
CONDENSED NOTES TO FINANCIAL STATEMENTS
March 31, 2006
--------------------------------------------------------------------------------

During January, 2004, the Company approved the issuance of stock options to its
board of directors to purchase a total of 270,000 shares of the Company's stock
at $0.42 per share for services rendered during the year ended December 31,
2004. The options vest immediately and have a term of ten years. In accordance
with Statement of Financial Accounting Standard No. 123, the fair value of the
options was estimated using the Black Scholes Option Price Calculation. The
following assumptions were made to value the stock options: strike price at
$0.10-$0.20; risk free interest rate of 4%; expected life of five to ten years;
and expected volatility of 62% to 92% with no dividends expected to be paid. The
Company recorded expenses totaling $515,173 ($0.10 per option for the value of
these options based upon these Black Scholes assumptions.

The following is a summary of the Company's equity compensation plans:

<TABLE>
<CAPTION>
                                                                                            Number of securities
                                     Number of securities to       Weighted-average       remaining available for
                                     be issued upon exercise      exercise price of        future issuance under
               Plan                   of outstanding options     outstanding options     equity compensation plans
----------------------------------- --------------------------- ----------------------- ----------------------------
<S>                                          <C>                        <C>                        <C>
Equity compensation plan approved            4,990,000                  $0.18                      260,000
  by security holders (1)
</TABLE>

(1) Omnibus Equity Incentive Plan

Following is a summary of the status of the options during the year ended
December 31, 2005 and the period ended March 31, 2006:

                                                                     Weighted
                                                                     Average
                                                      Number         Exercise
                                                    of Shares         Price
                                                   ------------    ------------
Outstanding at January 1, 2005                        6,357,953    $       0.17
Granted                                               5,178,453            0.15
Exercised                                                    --              --
Forfeited                                            (2,637,953)          (0.14)
                                                   ------------    ------------
Options outstanding at December 31, 2005              8,898,453            0.16
Granted                                                      --              --
Exercised                                                    --              --
Forfeited/Expired                                            --              --
                                                   ------------    ------------
Options outstanding and exercisable
  at March 31, 2006                                   8,898,453    $       0.16
                                                   ============    ============

                                       7
<PAGE>

ADVANCED BIOTHERAPY, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
CONDENSED NOTES TO FINANCIAL STATEMENTS
March 31, 2006
--------------------------------------------------------------------------------

Summarized information about stock options outstanding and exercisable at March
31, 2006 is as follows:

<TABLE>
<CAPTION>
                                           Outstanding and Exercisable Options
                          -----------------------------------------------------------------------
Exercise Price Range        Number of          Weighted Average             Weighted Average
                             Shares             Remaining Life               Exercise Price
---------------------     --------------    ------------------------     ------------------------
<S>                       <C>               <C>                          <C>
   $0.10 - $0.42            8,898,453                6.16                        $ 0.16
</TABLE>

NOTE 6 - NON-CASH COMMITMENT AND WARRANTS

During February 2003, the Company issued warrants to purchase a total of 100,000
shares of common stock to two outside consultants. These warrants have an
exercise price of $0.16 per share, expire in seven years, and vest over a period
of three years, with the first one-third of such warrants vesting in 2005, the
next one-third in 2005 and the remaining one-third vesting in 2006. In
accordance with Statement of Financial Accounting Standard No. 123, the fair
value of the warrants was estimated using the Black Scholes Option Price
Calculation. The following assumptions were made to value the stock warrants:
strike price at $0.16, risk free interest rate of 5%, expected life of seven
years, and expected volatility of 82% with no dividends expected to be paid. The
Company records an expense for the value of these warrants based upon these
Black Scholes assumptions of $12,300 ($0.123 per option) over the three years as
the warrants vest. During the three months ended March 31, 2006, the final
$4,100 was recorded under these warrants.

During the year ended December 31, 2004, a warrant to purchase 100,000 shares of
common stock was exercised using the cashless conversion feature, resulting in
the issuance of 47,917 shares of common stock.

Summarized information about stock warrants outstanding and exercisable at March
31, 2006, is as follows:

                    Number of         Weighted Average           Average
                    warrants           Remaining Life        exercise price
               ------------------    ------------------    ------------------
Outstanding         5,504,227                3.86                 $0.16
Exercisable         5,384,227                3.95                 $0.16

During 2005, the Company granted warrants to purchase up to 380,000 shares of
common stock at an exercise price of $0.10 - $0.20 per share for services.
Subject to the terms of such warrants, 260,000 warrants are presently
exercisable, and expire February 24, 2015 through August 24, 2015. The remaining
120,000 warrants vest 1/3 each year commencing December 31, 2006.

                                       8
<PAGE>

ADVANCED BIOTHERAPY, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
CONDENSED NOTES TO FINANCIAL STATEMENTS
March 31, 2006
--------------------------------------------------------------------------------

NOTE 7- CONCENTRATIONS

Bank Accounts and investments
The Company maintains cash in a money market account at a bank in California.
The funds on deposit are not insured by the FDIC and, therefore, a total of
$8,265 is at risk on March 31, 2006.

NOTE 8- COMMITMENTS AND CONTINGENCIES

The Company is not able to repay its convertible debt and other notes payable as
of June 1, 2006. The Company through a special committee of the Board of
Directors is exploring discussions with the lead holder of such convertible
notes (a director of the Company) regarding terms and conditions relating to
raising additional capital for the Company and modifying the convertible notes
to reduce the conversion price of such outstanding convertible notes and other
notes payable. No assurances can be given that any satisfactory arrangements
will be made with the convertible note holders, or, if the convertible note
holders propose a debt restructuring, that the Board of Directors will approve
any such arrangements. No assurances can be given that the holders of the
convertible notes would agree to defer payment beyond June 1, 2006. Absent any
other arrangements with the convertible note holders, it is expected that after
expiration of the applicable cure period, the Company will be in payment
default.

During the first quarter of 2005, the Company entered into an agreement,
approved by the Board of directors, with a consultant whereby the consultant
will utilize its established process and reasonable commercial efforts to secure
a commercial relationship with potential candidates. This commercial
relationship may include the license or transfer of intellectual property,
product rights, manufacturing rights, patents, or development assistance. A fee
will be paid to the consultant in the amount of $5,000 per month for services
provided between January 1, 2005 and September 30, 2005 upon the Company
receiving funding either in the form of a licensing agreement or equity or debt
financing. Additionally, the consultant will be reimbursed for reasonable
out-of-pocket costs. A success fee is included in the agreement if the Company
enters into a commercial relationship within eighteen months from the
termination of the agreement with a candidate brought to the Company by the
consultant.

NOTE 9 - SUBSEQUENT EVENTS

Subsequent to March 31, 2006, the Company received $48,000 from related parties
for conventional term notes and $38,000 from unrelated parties for term notes
convertible at $0.07 per share. All of these notes are due June 30, 2006 and
bear interest at 12% per annum.

                                       9
<PAGE>

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS.

      This Quarterly Report and other documents we file with the Securities and
Exchange Commission ("SEC") contain forward-looking statements that are based on
current expectations, estimates, forecasts and projections about us, our future
performance, our business, our beliefs and our management's assumptions. All
statements other than statements of historical facts are forward-looking
statements, including any statements of the plans and objectives of management
for future operations, any statements concerning proposed new product candidates
and prospects for regulatory approval, any projections of revenue earnings or
other financial items, any statements regarding future economic conditions or
performance, and any statement of assumptions underlying any of the foregoing.
Some of these forward-looking statements may be identified by the use of words
in the statements such as "anticipate," "estimate," "could" "expect," "project,"
"intend," "plan," "believe," "seek," "should," "may," "assume," "continue,"
variations of such words and similar expressions. These statements are not
guarantees of future performance and involve certain risks, uncertainties, and
assumptions that are difficult to predict. We caution you that our performance
and results could differ materially from what is expressed, implied, or forecast
by our forward-looking statements due to general financial, economic, regulatory
and political conditions affecting the biotechnology and pharmaceutical
industries as well as more specific risks and uncertainties. The Company
operates in a rapidly changing environment that involves a number of risks, some
of which are beyond the Company's control. Future operating results and the
Company's stock price may be affected by a number of factors, including, without
limitation: (i) availability of capital for research and development; (ii)
availability of capital for clinical trials; (iii) opportunities for joint
ventures and corporate partnering; (iv) opportunities for mergers and
acquisitions to expand the Company's biotechnology base or acquire revenue
generating products; (v) regulatory approvals of preclinical and clinical
trials; (vi) the results of preclinical and clinical trials, if any; (vii)
regulatory approvals of product candidates, new indications and manufacturing
facilities; (viii) health care guidelines and policies relating to prospective
Company products; (ix) intellectual property matters (patents); and (x)
competition. Factors that could cause or contribute to such differences include,
but are not limited to, those discussed in the section entitled "Item 1.
Business," and all subsections therein, including, without limitation, the
subsections entitled, Technical Background, Government Regulation, Federal Drug
Administration Regulation, Competition and Factors That May Affect the Company,
and the section entitled "Market for Registrant's Common Stock and Related
Stockholder Matters," all contained in the Company's Annual Report on Form
10-KSB for the fiscal year ended December 31, 2005. Given these risks and
uncertainties, any or all of these forward-looking statements may prove to be
incorrect. Therefore, you should not rely on any such forward-looking
statements. Furthermore, we do not intend (and we are not obligated) to update
publicly any forward-looking statements. You are advised, however, to consult
any further disclosures we make on related subjects in our reports to the
Securities and Exchange Commission.

                                       10
<PAGE>

OVERVIEW

      The Company had $9,265 in cash and investments as of March 31, 2006.
Management anticipates that current funds will enable the Company to continue
severely restricted operations through June 2006. This amount of cash is
inadequate to meet the Company's projected minimum cash requirements for full
operations for the next 12 months of approximately $6,400,000, including payment
of the current portion of convertible notes payable due June 1, 2006 in the
amount of $4,490,485 and other term notes due June 30, 2006, in the principal
amount of $236,500, including term notes received subsequent to March 31, 2006.

      The Company is not able to repay its convertible debt and other notes
payable as of June 1, 2006. The Company through a special committee of the Board
of Directors is exploring discussions with the lead holder of such convertible
notes (a director of the Company) regarding terms and conditions relating to
raising additional capital for the Company and modifying the convertible notes
to reduce the conversion price of such outstanding convertible notes and other
notes payable. No assurances can be given that any satisfactory arrangements
will be made with the convertible note holders, or, if the convertible note
holders propose a debt restructuring, that the Board of Directors will approve
any such arrangements. No assurances can be given that the holders of the
convertible notes would agree to defer payment beyond June 1, 2006. Absent any
other arrangements with the convertible note holders, it is expected that after
expiration of the applicable cure period, the Company will be in payment
default.

      The Company does not have a source of revenues to continue its operations,
or research and development costs beyond the current available funds. In order
to meet projected operational and research and development costs, the Company
will have to raise funds through the issuance, for cash, of common or preferred
stock, convertible debt or loans. There is no assurance, however, that the
Company will be able to raise sufficient capital to meet those cash requirements
for the next three months or longer.

      The Company has initiated reductions in certain research and development
projects and plans to postpone certain patent applications and other patent
matters. Management is monitoring the Company's funds and considering financing
alternatives with the Company's directors. In order to conserve resources,
management may consider delaying or discontinuing the filing of the Company's
periodic reports to the Securities and Exchange Commission.

      In terms of the Company's long-term convertible debt, as of March 31,
2006, the approximate principal balance of $4,483,085, $1,033,889 and $252,245
matures on June 1, 2006, September 30, 2007 and September 30, 2009,
respectively. Additionally, the Company owes $7,400 to one noteholder whose
convertible pay-in-kind note matured on September 30, 2004. The Company has
attempted unsuccessfully to locate this noteholder. During the first quarter of
2006, the Company also incurred non-convertible term debt due on June 30, 2006
in the cumulative amount of $150,000. Of that amount, $125,000 was loaned by an
officer and a director of the Company. Subsequent to M arch 31, 2006, the
Company received an additional (i) $38,000 in debt, convertible at $0.07 per
share at June 30, 2006, and (ii) $48,500 in new convertible term debt due June
30, 2006.

                                       11
<PAGE>

      The Company's business development plan for 2006, subject to satisfying
its convertible note and other note payable obligations and raising additional
capital, principally focuses on the following five specific elements:

      1.    Evaluation of possible merger, acquisition or sale candidates;
      2.    Evaluation of financing alternatives and opportunities;
      3.    Research and development as well as licensing agreements with
            selected pharmaceutical companies seeking opportunities related to
            our patented scientific approaches;
      4.    Continuation of our FDA approved Phase I clinical trial at
            Georgetown University Medical Center; and
      5.    Initiation of US clinical trials in a selected autoimmune skin
            disease.

      We believe that the Company is a leader in conducting investigational
clinical trials allowing us to secure intellectual property for anti-cytokine
based treatments of certain autoimmune diseases by the use of antibodies
directed at certain cytokines, most notably interferon-gamma and tumor necrosis
factor-alpha. We have no revenues or FDA-approved products, and cannot predict
when we might anticipate having proprietary marketed products. Accordingly, our
cash flows depend substantially on the success of our ability to enter into
licensing and royalty arrangements, and raise capital through the use of equity
or debt private placements.

      As described above, the Company seeks to establish collaborative
relationships with one or more pharmaceutical or biotechnological companies that
could result in the generation of licensing, milestone and royalty payments to
the Company. The Company is, therefore, seeking out-licensing or co-development
arrangements of its intellectual property that will generate recurring revenue
and cash flow. As of the date hereof, the Company has not entered into any
agreement with a pharmaceutical or biotechnological company, or any such
out-licensing arrangements.

      In general, we have a history of operating losses and have not generated
any revenue. As of March 31, 2006, we had an accumulated deficit of
approximately $13,834,800. Subject to raising capital and making satisfactory
arrangements with the holders of convertible notes that are due on June 1, 2006,
over the next several months, we expect to incur substantial additional expenses
as we continue to identify and develop potential products and invest in
research. Since we or potential collaborative partners or licensees may not be
able to successfully develop additional products, obtain required regulatory
approvals, manufacture products at an acceptable cost and with appropriate
quality, or successfully market such products with desired margins, we may never
achieve profitable operations. The amount of net losses and the time required to
reach sustained profitability are highly uncertain.

      The Company has no expected purchases or sales of significant equipment
and there are no expected significant changes in the number of employees of the
Company.

RESULTS OF OPERATIONS - Three months ended March 31, 2006 and 2005.

                                       12
<PAGE>

      The Company is considered to be in the development stage as defined in
Statement of Financial Accounting Standards No. 7. There have been no operations
since incorporation.

LIQUIDITY AND CAPITAL RESOURCES.

      To date, we have financed our operations through private placements of
equity and convertible debt securities. The Company had $9,265 in cash and cash
equivalents as of March 31, 2006 and had issued and outstanding 54,348,34654
shares of its Common Stock.

THREE MONTHS ENDED MARCH 31, 2006 COMPARED TO 2005.

      For the three months ended March 31, 2006, the Company realized a net loss
of $534,413 compared to a net loss of $623,066 for the three months ended March
31, 2005. The Company had decreases in expenses over the three months ended
March 31, 2005, consisting primarily of the following: decreased research and
development expenses of $91,008, decreased professional fees of $28,245,
decreased vesting of stock options and warrants of $20,500, decreased insurance
of $18,257, decreased shareholder relations and transfer fees expenses of
$5,690, decreased travel and entertainment of $13,533, and increased interest
expense of $26,853, net of increased administrative salaries and benefits of
$23,019.

ITEM 3. CONTROLS AND PROCEDURES

      In accordance with Item 307 of Regulation S-B promulgated under the
Securities Act of 1933, as amended, and within 90 days of the date of this
Quarterly Report on Form 10-QSB, the Chief Executive Officer and Chief Financial
Officer of the Company (the "Certifying Officers") have conducted evaluations of
the Company's disclosure controls and procedures. As defined under Sections
13a-14(c) and 15d-14(c) of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), the term "disclosure controls and procedures" means controls
and other procedures of an issuer that are designed to ensure that information
required to be disclosed by the issuer in the reports that it files or submits
under the Exchange Act is recorded, processed, summarized and reported, within
the time periods specified in the Commission's rules and forms. Disclosure
controls and procedures include, without limitation, controls and procedures
designed to ensure that information required to be disclosed by an issuer in the
reports that it files or submits under the Exchange Act is accumulated and
communicated to the issuer's management, including its principal executive
officer or officers and principal financial officer or officers, or persons
performing similar functions, as appropriate to allow timely decisions regarding
required disclosure. The Certifying Officers have reviewed the Company's
disclosure controls and procedures and have concluded that those disclosure
controls and procedures are effective in causing information to be recorded,
processed, summarized and reported within the time periods specified in the
Commission's rules and forms and communicated to management of the Company to
allow timely decisions regarding the Company's public disclosures. In compliance
with Section 302 of the Sarbanes-Oxley Act of 2002, (18 U.S.C. 1350), each of
the Certifying Officers executed an Officer's Certification included in this
Quarterly Report on Form 10-QSB.

                                       13
<PAGE>

      As of the date of this Quarterly Report on Form 10-QSB, there have not
been any significant changes in the Company's internal controls or in other
factors that could significantly affect these internal controls subsequent to
the date of the Certifying Officers' evaluation.

PART II

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

   (a)  Exhibit
        Number     Description

         31.1      Certification of Chief Executive Officer Pursuant to
                   Rule 13a-14(a).

         31.2      Certification of Chief Financial Officer Pursuant to
                   Rule 13a-14(a).

         32.1      Certification of Chief Executive Officer Pursuant to 18
                   U.S.C. Section 1350, as adopted pursuant to Section
                   906 of the Sarbanes-Oxley Act of 2002.

         32.2      Certification of Chief Financial Officer Pursuant to 18
                   U.S.C. Section 1350, as adopted pursuant to Section
                   906 of the Sarbanes-Oxley Act of 2002.

   (b) Reports on Form 8-K

      The Registrant filed the following reports on Form 8-K during the quarter
ended March 31, 2006:

      1. March 22, 2006. The Registrant reported that Advanced Biotherapy, Inc.
has entered into an initial Memorandum of Understanding (MOU) with Battelle for
the development and use of monoclonal antibodies to treat humans and animals
exposed to anthrax and plague as well as autoimmune diseases.

                                       14
<PAGE>

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report on Form 10-QSB to be signed on its behalf
by the undersigned thereunto duly authorized as of May 18, 2006.

                                           Advanced Biotherapy, Inc.
                                           (Registrant)

By: /s/Edmond F. Buccellato                By:  /s/William M. Finkelstein
    -----------------------                     -------------------------
    Edmond F. Buccellato                        William M. Finkelstein
    President and CEO                           Chief Financial Officer

                                       15
<PAGE>

                                  EXHIBIT INDEX

Exhibit                            Description
-------                            -----------

  31.1      Certification of Chief Executive Officer Pursuant to
            Rule 13a-14(a).

  31.2      Certification of Chief Financial Officer Pursuant to
            Rule 13a-14(a).

  32.1      Certification of Chief Executive Officer Pursuant to 18
            U.S.C. Section 1350, as adopted pursuant to Section
            906 of the Sarbanes-Oxley Act of 2002.

  32.2      Certification of Chief Financial Officer Pursuant to 18
            U.S.C. Section 1350, as adopted pursuant to Section
            906 of the Sarbanes-Oxley Act of 2002.

                                       16
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>v043962_ex31-1.txt
<TEXT>
                                                                    EXHIBIT 31.1


  Certification by Edmond F. Buccellato, President and Chief Executive Officer
                                       of
                            Advanced Biotherapy, Inc.

I, Edmond F. Buccellato, certify that:

1.    I have reviewed this quarterly report on Form 10-QSB of Advanced
      Biotherapy, Inc.;

2.    Based on my knowledge, this quarterly report does not contain any untrue
      statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by
      this quarterly report;

3.    Based on my knowledge, the financial statements, and other financial
      information included in this quarterly report, fairly present in all
      material respects the financial condition, results of operations and cash
      flows of the Registrant as of, and for, the periods presented in this
      quarterly report;

4.    The Registrant's other certifying officers and I are responsible for
      establishing and maintaining disclosure controls and procedures (as
      defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
      control over financial reporting (as defined in Exchange Act Rules
      13a-15(f) and 15d-15(f)) for the Registrant and have:

      a)    designed such disclosure controls and procedures, or caused such
            disclosure controls and procedures to be designed under our
            supervision, to ensure that material information relating to the
            Registrant, including its consolidated subsidiaries, is made known
            to us by others within those entities, particularly during the
            period in which this quarterly report is being prepared;

      b)    designed such internal control over financial reporting, or caused
            such internal control over financial reporting to be designed under
            our supervision, to provide reasonable assurance regarding the
            reliability of financial reporting and the preparation of financial
            statements for external purposes in accordance with generally
            accepted accounting principles;

      c)    evaluated the effectiveness of the Registrant's disclosure controls
            and procedures and presented in this report our conclusions about
            the effectiveness of the disclosure controls and procedures; and

      d)    disclosed in this report any change in the Registrant's internal
            control over financial reporting that occurred during the
            Registrant's most recent fiscal quarter that has materially
            affected, or is reasonably likely to materially affect, the
            Registrant's internal control over financial reporting.

5.    The Registrant's other certifying officers and I have disclosed, based on
      our most recent evaluation, to the Registrant's auditors and the audit
      committee of Registrant's board of directors (or persons performing the
      equivalent functions):

      a)    all significant deficiencies and material weaknesses in the design
            or operation of internal control over financial reporting which are
            reasonably likely to adversely affect the Registrant's ability to
            record, process, summarize and report financial information; and

      b)    any fraud, whether or not material, that involves management or
            other employees who have a significant role in the Registrant's
            internal control over financial reporting.

Date: May 18, 2006

                                           /s/Edmond F. Buccellato
                                           -----------------------
                                           Edmond F. Buccellato
                                           President and Chief Executive Officer
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>v043962_ex31-2.txt
<TEXT>
                                                                    EXHIBIT 31.2

        Certification by William M. Finkelstein, Chief Financial Officer
                                       of
                            Advanced Biotherapy, Inc.

I, William M. Finkelstein, certify that:

1.    I have reviewed this quarterly report on Form 10-QSB of Advanced
      Biotherapy, Inc.;

2.    Based on my knowledge, this quarterly report does not contain any untrue
      statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by
      this quarterly report;

3.    Based on my knowledge, the financial statements, and other financial
      information included in this quarterly report, fairly present in all
      material respects the financial condition, results of operations and cash
      flows of the Registrant as of, and for, the periods presented in this
      quarterly report;

4.    The Registrant's other certifying officers and I are responsible for
      establishing and maintaining disclosure controls and procedures (as
      defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
      control over financial reporting (as defined in Exchange Act Rules
      13a-15(f) and 15d-15(f)) for the Registrant and have:

      a)    designed such disclosure controls and procedures, or caused such
            disclosure controls and procedures to be designed under our
            supervision, to ensure that material information relating to the
            Registrant, including its consolidated subsidiaries, is made known
            to us by others within those entities, particularly during the
            period in which this quarterly report is being prepared;

      b)    designed such internal control over financial reporting, or caused
            such internal control over financial reporting to be designed under
            our supervision, to provide reasonable assurance regarding the
            reliability of financial reporting and the preparation of financial
            statements for external purposes in accordance with generally
            accepted accounting principles;

      c)    evaluated the effectiveness of the Registrant's disclosure controls
            and procedures and presented in this report our conclusions about
            the effectiveness of the disclosure controls and procedures; and

      d)    disclosed in this report any change in the Registrant's internal
            control over financial reporting that occurred during the
            Registrant's most recent fiscal quarter that has materially
            affected, or is reasonably likely to materially affect, the
            Registrant's internal control over financial reporting.

5.    The Registrant's other certifying officers and I have disclosed, based on
      our most recent evaluation, to the Registrant's auditors and the audit
      committee of Registrant's board of directors (or persons performing the
      equivalent functions):

      a)    all significant deficiencies and material weaknesses in the design
            or operation of internal control over financial reporting which are
            reasonably likely to adversely affect the Registrant's ability to
            record, process, summarize and report financial information; and

      b)    any fraud, whether or not material, that involves management or
            other employees who have a significant role in the Registrant's
            internal control over financial reporting.

Date: May 18, 2006

                                                    /s/William M. Finkelstein
                                                    -------------------------
                                                    William M. Finkelstein
                                                    Chief Financial Officer
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>v043962_ex32-1.txt
<TEXT>
                                                                    EXHIBIT 32.1

                    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
                                   PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

      In connection with the Quarterly Report of Advanced Biotherapy, Inc. (the
"Company") on Form 10-QSB for the quarter ended March 31, 2006, as filed with
the Securities and Exchange Commission on the date hereof (the "Periodic
Report"), I, Edmond F. Buccellato, President and Chief Executive Officer of the
Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that:

      1.    the Periodic Report fully complies with the requirements of Section
            13(a) or 15(d) of the Securities Exchange Act of 1934; and

      2.    the information contained in the Periodic Report fairly presents, in
            all material respects, the financial condition and results of
            operations of the Company.

Dated: May 18, 2006                         /s/Edmond F. Buccellato
                                            -----------------------
                                            Edmond F. Buccellato, President and
                                            Chief Executive Officer
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>v043962_ex32-2.txt
<TEXT>
                                                                    EXHIBIT 32.2

                    CERTIFICATION OF CHIEF FINANCIAL OFFICER
                                   PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

      In connection with the Quarterly Report of Advanced Biotherapy, Inc. (the
"Company") on Form 10-QSB for the quarter ended March 31, 2006, as filed with
the Securities and Exchange Commission on the date hereof (the "Periodic
Report"), I, William M. Finkelstein, Chief Financial Officer of the Company,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that:

      1.    the Periodic Report fully complies with the requirements of Section
            13(a) or 15(d) of the Securities Exchange Act of 1934; and

      2.    the information contained in the Periodic Report fairly presents, in
            all material respects, the financial condition and results of
            operations of the Company.

Dated: May 18, 2006                                  /s/William M. Finkelstein
                                                     -------------------------
                                                     Chief Financial Officer
</TEXT>
</DOCUMENT>
</SUBMISSION>
